AIM
CTMX icon

Aigen Investment Management’s CytomX Therapeutics CTMX Stock Holding History

Aigen Investment Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-11,018
Closed -$92K – 893
2020
Q2 		$92K Buy
+11,018
New +$102K 0.01% 763

Other funds holding CTMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aigen Investment Management's CTMX Position: Q3 2020 in Review

Aigen Investment Management sold out of CytomX Therapeutics (CTMX) in Q3 2020, closing a stake of 11,018 shares — an estimated $92K sold.

Aigen Investment Management first reported a position in CTMX in Q2 2020 and held it in 1 quarter. The position peaked at $92K in Q2 2020. 130 funds tracked by Wall St. Rank hold CTMX as of Q3 2020.

  • Aigen Investment Management reported no remaining CytomX Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Aigen Investment Management sold 11,018 CytomX Therapeutics shares in Q3 2020, an estimated $92K.
  • Aigen Investment Management first reported a position in CytomX Therapeutics in Q2 2020 and held it in 1 quarter.
  • Aigen Investment Management's CytomX Therapeutics position peaked at $92K in Q2 2020.
  • 130 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2020.

Based on Aigen Investment Management's 13F filing for Q3 2020, filed 6 Nov 2020.